CDK4 and prostate cancer: The absence of AR activity has been shown to lead to reduced levels of cyclin D3 and cyclin A, reduced CDK4 and CDK2 activity, the hypophosphorylation of Rb, and G1 arrest in prostate cancer cells [46].